CODX vs CTAS · rev $3.9M vs P/E 51, rev $10.34B
Co-Diagnostics, Inc. Common Stock (CODX) versus Cintas Corporation (CTAS) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
CODX currently screens at market cap $31.4M. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Not investment advice. Open the CODX and CTAS stock pages for the full models.
Not investment advice.